Achieve Life Sciences (ACHV) Stock Overview
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ACHV Community Fair Values
Create NarrativeSee what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Achieve Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.28 |
| 52 Week High | US$6.03 |
| 52 Week Low | US$1.84 |
| Beta | 1.84 |
| 1 Month Change | -24.38% |
| 3 Month Change | -6.55% |
| 1 Year Change | 30.09% |
| 3 Year Change | -12.65% |
| 5 Year Change | -71.10% |
| Change since IPO | -99.51% |
Recent News & Updates
Recent updates
Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy
Feb 04Is Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?
Feb 15
Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement
Jul 01Does Achieve Life Sciences (NASDAQ:ACHV) Have A Healthy Balance Sheet?
Jan 27Is Achieve Life Sciences (NASDAQ:ACHV) Using Debt In A Risky Way?
Oct 26Shareholder Returns
| ACHV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.7% | 0.8% | 1.4% |
| 1Y | 30.1% | 29.0% | 13.2% |
Return vs Industry: ACHV matched the US Biotechs industry which returned 29.7% over the past year.
Return vs Market: ACHV exceeded the US Market which returned 14% over the past year.
Price Volatility
| ACHV volatility | |
|---|---|
| ACHV Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ACHV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACHV's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 25 | Rick Stewart | www.achievelifesciences.com |
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol.
Achieve Life Sciences, Inc. Fundamentals Summary
| ACHV fundamental statistics | |
|---|---|
| Market cap | US$232.10m |
| Earnings (TTM) | -US$52.35m |
| Revenue (TTM) | n/a |
Is ACHV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACHV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$52.35m |
| Earnings | -US$52.35m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 29.4% |
How did ACHV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/11 14:00 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Achieve Life Sciences, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CG Capital |
| Gary Nachman | CGS International |
| Jason Butler | Citizens JMP Securities, LLC |